First National Bank of Hutchinson Boosts Stock Holdings in Eli Lilly and Company (NYSE:LLY)

First National Bank of Hutchinson grew its position in Eli Lilly and Company (NYSE:LLY) by 17.1% during the 4th quarter, HoldingsChannel.com reports. The fund owned 2,019 shares of the company’s stock after buying an additional 295 shares during the quarter. Eli Lilly and Company makes up about 0.9% of First National Bank of Hutchinson’s portfolio, making the stock its 22nd largest holding. First National Bank of Hutchinson’s holdings in Eli Lilly and Company were worth $1,559,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the company. Sandy Spring Bank raised its stake in Eli Lilly and Company by 9.7% in the 4th quarter. Sandy Spring Bank now owns 21,004 shares of the company’s stock valued at $16,215,000 after purchasing an additional 1,853 shares during the last quarter. Arvest Investments Inc. grew its holdings in shares of Eli Lilly and Company by 4.0% during the fourth quarter. Arvest Investments Inc. now owns 905 shares of the company’s stock worth $699,000 after buying an additional 35 shares in the last quarter. Royal London Asset Management Ltd. raised its position in shares of Eli Lilly and Company by 2.6% in the fourth quarter. Royal London Asset Management Ltd. now owns 741,294 shares of the company’s stock valued at $572,279,000 after buying an additional 18,925 shares during the last quarter. Trivest Advisors Ltd purchased a new position in shares of Eli Lilly and Company in the fourth quarter worth about $10,808,000. Finally, First Financial Bankshares Inc grew its stake in Eli Lilly and Company by 2.0% during the 4th quarter. First Financial Bankshares Inc now owns 1,011 shares of the company’s stock valued at $780,000 after acquiring an additional 20 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 1,000 shares of the company’s stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total value of $818,240.00. Following the completion of the sale, the chief accounting officer now owns 5,840 shares in the company, valued at $4,778,521.60. This represents a 14.62 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.13% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on LLY shares. Berenberg Bank set a $970.00 target price on Eli Lilly and Company in a report on Thursday, January 16th. Bank of America reissued a “buy” rating and set a $997.00 price objective on shares of Eli Lilly and Company in a research note on Tuesday, December 10th. Truist Financial lifted their price target on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a “buy” rating in a report on Monday, February 3rd. Wells Fargo & Company boosted their target price on shares of Eli Lilly and Company from $970.00 to $1,100.00 and gave the company an “overweight” rating in a report on Wednesday, March 5th. Finally, StockNews.com raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Friday, February 7th. Three analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $1,009.72.

Eli Lilly and Company Stock Up 1.8 %

Shares of NYSE:LLY opened at $837.34 on Thursday. The firm has a 50 day simple moving average of $834.04 and a 200-day simple moving average of $840.69. Eli Lilly and Company has a twelve month low of $711.40 and a twelve month high of $972.53. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. The company has a market capitalization of $793.94 billion, a PE ratio of 71.51, a P/E/G ratio of 1.40 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. On average, equities analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company announced that its Board of Directors has approved a share repurchase plan on Monday, December 9th that allows the company to repurchase $15.00 billion in shares. This repurchase authorization allows the company to repurchase up to 2% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company’s board believes its shares are undervalued.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.